ChemPartner PharmaTechLtd Dirección

Dirección controles de criterios 1/4

El CEO de ChemPartner PharmaTechLtd's es Swee Lian Woo, nombrado en Jan 2024, tiene una permanencia de menos de un año. posee directamente un 4.56% de las acciones de la empresa, con un valor de CN¥107.88M. La antigüedad media del equipo directivo y de la junta directiva es de 1.3 años y 2.9 años, respectivamente.

Información clave

Swee Lian Woo

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	4.6%
Permanencia media de la dirección	1.5yrs
Promedio de permanencia en la Junta Directiva	3yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Swee Lian Woo (63 yo)

less than a year

Permanencia

Mr. Swee Lian Woo is President of Perfect (China) Co., Ltd. He is Director of RRTC, Inc. He serves as General Manager and Chairman of Chempartner Pharmatech Co., Ltd. since January 10, 2024.He was Chairma...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jian Xu	Board Secretary	2.9yrs	CN¥1.44m	sin datos
Zhenjia Chen	Vice President	1.5yrs	CN¥1.78m	sin datos
Swee Lian Woo	GM & Chairman	less than a year	sin datos	4.56% CN¥ 142.6m

1.5yrs

Permanencia media

63yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 300149 no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Swee Lian Woo	GM & Chairman	less than a year	sin datos	4.56% CN¥ 142.6m
Xin Hui	Director	6.3yrs	CN¥360.00k	sin datos
Rong Yu	Director	less than a year	sin datos	sin datos
Dachao Zhang	Chairman of the Supervisory Board	3.2yrs	sin datos	sin datos
Zhicheng Guo	Independent Director	4.1yrs	CN¥80.00k	sin datos
Shi Xin Fan	Director	2.9yrs	CN¥1.03m	sin datos
Xianzhong Wang	Independent Director	3.2yrs	CN¥80.00k	0.00030% CN¥ 9.4k
Jiahui Qi	Supervisor	6.3yrs	sin datos	0.0084% CN¥ 263.6k
Ling Yang	Independent Director	1.8yrs	CN¥80.00k	sin datos
Man Ngar Wong	Employee Supervisor	1.6yrs	sin datos	sin datos

3.0yrs

Permanencia media

53.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 300149 se considera experimentada (3 años de antigüedad promedio).

ChemPartner PharmaTechLtd Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 31, 2024

Less than half of directors are independent

Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 23, 2022

Less than half of directors are independent

Recent updates

ChemPartner PharmaTech Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: CN¥0.076 loss per share (vs CN¥0.011 profit in 2Q 2023)

ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 31, 2024

First quarter 2024 earnings released: CN¥0.051 loss per share (vs CN¥0.057 loss in 1Q 2023)

New minor risk - Share price stability

Chempartner Pharmatech Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Chempartner Pharmatech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

Third quarter 2023 earnings released: CN¥0.048 loss per share (vs CN¥0.13 profit in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.011 (vs CN¥1.90 in 2Q 2022)

Investor sentiment deteriorates as stock falls 15%

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

First quarter 2023 earnings released: CN¥0.057 loss per share (vs CN¥0.019 profit in 1Q 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.021 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥1.90 (vs CN¥0.007 in 2Q 2021)

Tate & Lyle Investments Limited completed the acquisition of Quantum Hi-Tech (Guangdong) Biological Co., Ltd. from Chempartner Pharmatech Co., Ltd. (SZSE:300149).

Tate & Lyle plc (LSE:TATE) completed the acquisition of Guangdong Quantum Hi-Tech Microecology Medical Co., Ltd. from Chempartner Pharmatech Co., Ltd. (SZSE:300149).

Chempartner Pharmatech Co., Ltd. announced that it expects to receive CNY 300 million in funding

Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 23, 2022

First quarter 2022 earnings released: EPS: CN¥0.019 (vs CN¥0.003 in 1Q 2021)

Chempartner Pharmatech Co., Ltd. to Report Fiscal Year 2021 Results on Apr 30, 2022

Less than half of directors are independent

Tate & Lyle plc (LSE:TATE) signed an agreement to acquire Guangdong Quantum Hi-Tech Microecology Medical Co., Ltd. from Chempartner Pharmatech Co., Ltd. (SZSE:300149) for $237 million.

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS CN¥0.007 (vs CN¥0.11 in 2Q 2020)

Chempartner Pharmatech Co., Ltd. Announces Final Cash Dividend for 2020, Payable on 1 June 2021

Chempartner Pharmatech Co., Ltd. Approves Cash Dividend for the Year 2020

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.003 (vs CN¥0.028 loss in 1Q 2020)

Chempartner Pharmatech Co., Ltd. Announces the Profit Distribution Proposal for 2020

New 90-day low: CN¥12.64

New 90-day low: CN¥12.66

Investor sentiment deteriorated over the past week

New 90-day low: CN¥14.46

New 90-day low: CN¥18.29

Third quarter earnings released

New 90-day high - CN¥23.98

First half earnings released

Quantum Hi-Tech (China) Biological Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

New 90-day high - CN¥22.71

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad